{
    "xml": "<topic id=\"PHP107124\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/recivit-sublingual-tablets\" basename=\"recivit-sublingual-tablets\" title=\"Recivit sublingual tablets\">\n<title>Recivit<tm tmtype=\"reg\"/> sublingual tablets</title>\n<topic id=\"PHP107134\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/clinical-medicinal-product-information/recivit-sublingual-tablets\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Breakthrough pain in patients receiving opioid therapy for chronic cancer pain</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 133&#8239;micrograms, then 133&#8239;micrograms after 15&#8211;30&#8239;minutes (max. per dose 800&#8239;micrograms), dose to be repeated only if necessary. Consult product literature for dose adjustments, no more than 2 dose units, 15-30 minutes apart, for each pain episode, maximum of 800&#8239;micrograms per episode of breakthrough pain, if more than 4 episodes of breakthrough pain each day, adjust background analgesia; maximum 4&#8239;doses per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP107175\" outputclass=\"patientAndCarerAdvice\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/recivit-sublingual-tablets\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed. In patients with a dry mouth, the buccal mucosa may be moistened with water before administration of tablet.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP107124",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/recivit-sublingual-tablets",
    "basename": "recivit-sublingual-tablets",
    "title": "Recivit sublingual tablets",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Breakthrough pain in patients receiving opioid therapy for chronic cancer pain",
                        "html": "Breakthrough pain in patients receiving opioid therapy for chronic cancer pain"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 133 micrograms, then 133 micrograms after 15&#8211;30 minutes (max. per dose 800 micrograms), dose to be repeated only if necessary. Consult product literature for dose adjustments, no more than 2 dose units, 15-30 minutes apart, for each pain episode, maximum of 800 micrograms per episode of breakthrough pain, if more than 4 episodes of breakthrough pain each day, adjust background analgesia; maximum 4 doses per day.",
                        "html": "<p>Initially 133&#8239;micrograms, then 133&#8239;micrograms after 15&#8211;30&#8239;minutes (max. per dose 800&#8239;micrograms), dose to be repeated only if necessary. Consult product literature for dose adjustments, no more than 2 dose units, 15-30 minutes apart, for each pain episode, maximum of 800&#8239;micrograms per episode of breakthrough pain, if more than 4 episodes of breakthrough pain each day, adjust background analgesia; maximum 4&#8239;doses per day.</p>"
                    }
                ]
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed. In patients with a dry mouth, the buccal mucosa may be moistened with water before administration of tablet.",
                "html": "<p>Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed. In patients with a dry mouth, the buccal mucosa may be moistened with water before administration of tablet.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}